Suppr超能文献

[Pt(1S,2S-二氨基环己烷)(5,6-二甲基-1,10-菲咯啉)]的铂(IV)衍生物的合成、表征及体外和体内抗癌活性

Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(iv) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)].

作者信息

Harper Benjamin W J, Petruzzella Emanuele, Sirota Roman, Faccioli Fernanda Fabiola, Aldrich-Wright Janice R, Gandin Valentina, Gibson Dan

机构信息

Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem, 91120, Israel.

出版信息

Dalton Trans. 2017 May 30;46(21):7005-7019. doi: 10.1039/c7dt01054k.

Abstract

This report describes the synthesis, characterization and biological activity of a series of platinum(iv) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)] (Pt56MeSS) with non-bioactive, lipophilic and bioactive axial ligands. In an attempt to explore the anticancer activity potential of the Pt(iv) derivatives, 2D and 3D cytotoxic screening and a preliminary in vivo study were performed. The average IC values of the platinum(iv) derivatives ranged from 1.26 to 5.39 μM, compared with 1.24 μM for Pt56MeSS, suggesting that the axial ligands have a relatively minor effect on the potency of the compounds. Preliminary in vivo studies indicate that the platinum(iv) derivatives of Pt56MeSS are active in vivo and can reduce the tumor to a similar extent to cisplatin.

摘要

本报告描述了一系列具有非生物活性、亲脂性和生物活性轴向配体的[Pt(1S,2S - DACH)(5,6 - 二甲基 - 1,10 - 菲咯啉)](Pt56MeSS)铂(IV)衍生物的合成、表征及生物活性。为探索铂(IV)衍生物的抗癌活性潜力,进行了二维和三维细胞毒性筛选以及初步的体内研究。铂(IV)衍生物的平均IC值范围为1.26至5.39 μM,而Pt56MeSS为1.24 μM,这表明轴向配体对化合物的效力影响相对较小。初步的体内研究表明,Pt56MeSS的铂(IV)衍生物在体内具有活性,并且可以将肿瘤缩小到与顺铂相似的程度。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验